|
English
|
正體中文
|
简体中文
|
0
|
|
???header.visitor??? :
52691920
???header.onlineuser??? :
1057
???header.sponsordeclaration???
|
|
|
|
???tair.name??? >
???browser.page.title.author???
|
"_"???jsp.browse.items-by-author.description???
Showing items 841-850 of 4992 (500 Page(s) Totally)
<< < 80 81 82 83 84 85 86 87 88 89 > >>
View [10|25|50] records per page
| 國立成功大學 |
2024-06 |
Vibostolimab coformulated with pembrolizumab (vibo/ pembro) plus chemotherapy (chemo) as first-line treatment for advanced esophageal cancer (ec): Results from cohort E of the phase II KEYVIBE-005 study
|
Hsu;C-H;Dziadziuszko;R;Abreo, Gomez;D, A.;Aksoy;S;Martin, Gil;M;Roderburg;C;Yen;C, J.;Arican;A;Cassier;P;Im;S-A;Kim;S-B;Kudo;T;Ochsenreither;S;Sendur;M, A. N.;Yonemori;K;Rojas;C, I.;Liu;Q;Keenan;T;Healy;J;Kwiatkowski;M |
| 國立成功大學 |
2024-06 |
An inverse method of fundamental solutions for the identification of 2D elastic properties of anisotropic solids
|
Hematiyan;M, R.;Khosravifard;A;Mohammadi;M;Shiah;Y, C. |
| 國立成功大學 |
2024-06 |
Investigating the protective role of CD44 and microRNA-146a in tendinopathic tenocytes: a signaling axis regulating apoptosis
|
Chen;S;Wu;P |
| 國立成功大學 |
2024-06 |
Vibostolimab coformulated with pembrolizumab (vibo/ pembro) plus chemotherapy (chemo) as first-line treatment for advanced esophageal cancer (ec): Results from cohort E of the phase II KEYVIBE-005 study
|
Hsu;C-H;Dziadziuszko;R;Abreo, Gomez;D, A.;Aksoy;S;Martin, Gil;M;Roderburg;C;Yen;C, J.;Arican;A;Cassier;P;Im;S-A;Kim;S-B;Kudo;T;Ochsenreither;S;Sendur;M, A. N.;Yonemori;K;Rojas;C, I.;Liu;Q;Keenan;T;Healy;J;Kwiatkowski;M |
| 國立成功大學 |
2024-06 |
Vibostolimab coformulated with pembrolizumab (vibo/ pembro) plus chemotherapy (chemo) as first-line treatment for advanced esophageal cancer (ec): Results from cohort E of the phase II KEYVIBE-005 study
|
Hsu;C-H;Dziadziuszko;R;Abreo, Gomez;D, A.;Aksoy;S;Martin, Gil;M;Roderburg;C;Yen;C, J.;Arican;A;Cassier;P;Im;S-A;Kim;S-B;Kudo;T;Ochsenreither;S;Sendur;M, A. N.;Yonemori;K;Rojas;C, I.;Liu;Q;Keenan;T;Healy;J;Kwiatkowski;M |
| 國立成功大學 |
2024-06 |
Vibostolimab coformulated with pembrolizumab (vibo/ pembro) plus chemotherapy (chemo) as first-line treatment for advanced esophageal cancer (ec): Results from cohort E of the phase II KEYVIBE-005 study
|
Hsu;C-H;Dziadziuszko;R;Abreo, Gomez;D, A.;Aksoy;S;Martin, Gil;M;Roderburg;C;Yen;C, J.;Arican;A;Cassier;P;Im;S-A;Kim;S-B;Kudo;T;Ochsenreither;S;Sendur;M, A. N.;Yonemori;K;Rojas;C, I.;Liu;Q;Keenan;T;Healy;J;Kwiatkowski;M |
| 國立成功大學 |
2024-06 |
Investigating the protective role of CD44 and microRNA-146a in tendinopathic tenocytes: a signaling axis regulating apoptosis
|
Chen;S;Wu;P |
| 國立成功大學 |
2024-06 |
The hepatic fibrogenic effect of aberrant IgG-Fc glycosylation
|
Ho;C;Chang;T;Wang;S |
| 國立成功大學 |
2024-06 |
Exosomal EPHA2 and EHD1 proteins promote lung cancer metastasis
|
Chen;Y;Weng;S;Hong;T |
| 國立成功大學 |
2024-06 |
The oncogenic role and clinical significance of RNA N6-methyladenosine regulator METTL3 and IGF2BP3 in hepatocellular carcinoma
|
Wang;W;Huang;Y;Wang;S;Yen;C |
Showing items 841-850 of 4992 (500 Page(s) Totally)
<< < 80 81 82 83 84 85 86 87 88 89 > >>
View [10|25|50] records per page
|
